Protective role of mirtazapine in adult female Mecp2+/− mice and patients with Rett syndrome

Rett syndrome (RTT), an X-linked neurodevelopmental rare disease mainly caused by MECP2-gene mutations, is a prototypic intellectual disability disorder. Reversibility of RTT-like phenotypes in an adult mouse model lacking the Mecp2-gene has given hope of treating the disease at any age. However, ad...

Full description

Saved in:
Bibliographic Details
Published inJournal of neurodevelopmental disorders Vol. 12; no. 1; pp. 26 - 20
Main Authors Flores Gutiérrez, Javier, De Felice, Claudio, Natali, Giulia, Leoncini, Silvia, Signorini, Cinzia, Hayek, Joussef, Tongiorgi, Enrico
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 28.09.2020
BioMed Central
BMC
Subjects
Age
Amygdala
Analysis
Animals
Antidepressants
Behavior
Biopsy
Cortex (barrel)
Cortex (motor)
Deoxyribonucleic acid
DNA
Ethanol
Females
Gene mutation
Genetic aspects
Genotype & phenotype
Hypersensitivity
Intellectual disabilities
Intellectual disability disorders
Irritability/aggressiveness
Laboratories
MeCP2 protein
Methyl-CpG binding protein
Mirtazapine
Mood
Motor learning deficits
Motor skill
Motor skill learning
Mutation
Neurodevelopmental disorders
Norepinephrine
Parvalbumin
Patients
Phenotypes
Rare diseases
Rett syndrome
Rodents
Sleep disorders
Social aspects
Social behavior
Somatosensory cortex
United States > US
Intellectual disability disorders
Somatosensory cortex
Irritability/aggressiveness
Parvalbumin neurons
Motor learning deficits
Antidepressants
Rett syndrome
Online AccessGet full text

Cover

Abstract Rett syndrome (RTT), an X-linked neurodevelopmental rare disease mainly caused by MECP2-gene mutations, is a prototypic intellectual disability disorder. Reversibility of RTT-like phenotypes in an adult mouse model lacking the Mecp2-gene has given hope of treating the disease at any age. However, adult RTT patients still urge for new treatments. Given the relationship between RTT and monoamine deficiency, we investigated mirtazapine (MTZ), a noradrenergic and specific-serotonergic antidepressant, as a potential treatment. Adult heterozygous-Mecp2 (HET) female mice (6-months old) were treated for 30 days with 10 mg/kg MTZ and assessed for general health, motor skills, motor learning, and anxiety. Motor cortex, somatosensory cortex, and amygdala were analyzed for parvalbumin expression. Eighty RTT adult female patients harboring a pathogenic MECP2 mutation were randomly assigned to treatment to MTZ for insomnia and mood disorders (mean age = 23.1 ± 7.5 years, range = 16-47 years; mean MTZ-treatment duration = 1.64 ± 1.0 years, range = 0.08-5.0 years). Rett clinical severity scale (RCSS) and motor behavior assessment scale (MBAS) were retrospectively analyzed. In HET mice, MTZ preserved motor learning from deterioration and normalized parvalbumin levels in the primary motor cortex. Moreover, MTZ rescued the aberrant open-arm preference behavior observed in HET mice in the elevated plus-maze (EPM) and normalized parvalbumin expression in the barrel cortex. Since whisker clipping also abolished the EPM-related phenotype, we propose it is due to sensory hypersensitivity. In patients, MTZ slowed disease progression or induced significant improvements for 10/16 MBAS-items of the M1 social behavior area: 4/7 items of the M2 oro-facial/respiratory area and 8/14 items of the M3 motor/physical signs area. This study provides the first evidence that long-term treatment of adult female heterozygous Mecp2 mice and adult Rett patients with the antidepressant mirtazapine is well tolerated and that it protects from disease progression and improves motor, sensory, and behavioral symptoms.
AbstractList Rett syndrome (RTT), an X-linked neurodevelopmental rare disease mainly caused by MECP2-gene mutations, is a prototypic intellectual disability disorder. Reversibility of RTT-like phenotypes in an adult mouse model lacking the Mecp2-gene has given hope of treating the disease at any age. However, adult RTT patients still urge for new treatments. Given the relationship between RTT and monoamine deficiency, we investigated mirtazapine (MTZ), a noradrenergic and specific-serotonergic antidepressant, as a potential treatment.BACKGROUNDRett syndrome (RTT), an X-linked neurodevelopmental rare disease mainly caused by MECP2-gene mutations, is a prototypic intellectual disability disorder. Reversibility of RTT-like phenotypes in an adult mouse model lacking the Mecp2-gene has given hope of treating the disease at any age. However, adult RTT patients still urge for new treatments. Given the relationship between RTT and monoamine deficiency, we investigated mirtazapine (MTZ), a noradrenergic and specific-serotonergic antidepressant, as a potential treatment.Adult heterozygous-Mecp2 (HET) female mice (6-months old) were treated for 30 days with 10 mg/kg MTZ and assessed for general health, motor skills, motor learning, and anxiety. Motor cortex, somatosensory cortex, and amygdala were analyzed for parvalbumin expression. Eighty RTT adult female patients harboring a pathogenic MECP2 mutation were randomly assigned to treatment to MTZ for insomnia and mood disorders (mean age = 23.1 ± 7.5 years, range = 16-47 years; mean MTZ-treatment duration = 1.64 ± 1.0 years, range = 0.08-5.0 years). Rett clinical severity scale (RCSS) and motor behavior assessment scale (MBAS) were retrospectively analyzed.METHODSAdult heterozygous-Mecp2 (HET) female mice (6-months old) were treated for 30 days with 10 mg/kg MTZ and assessed for general health, motor skills, motor learning, and anxiety. Motor cortex, somatosensory cortex, and amygdala were analyzed for parvalbumin expression. Eighty RTT adult female patients harboring a pathogenic MECP2 mutation were randomly assigned to treatment to MTZ for insomnia and mood disorders (mean age = 23.1 ± 7.5 years, range = 16-47 years; mean MTZ-treatment duration = 1.64 ± 1.0 years, range = 0.08-5.0 years). Rett clinical severity scale (RCSS) and motor behavior assessment scale (MBAS) were retrospectively analyzed.In HET mice, MTZ preserved motor learning from deterioration and normalized parvalbumin levels in the primary motor cortex. Moreover, MTZ rescued the aberrant open-arm preference behavior observed in HET mice in the elevated plus-maze (EPM) and normalized parvalbumin expression in the barrel cortex. Since whisker clipping also abolished the EPM-related phenotype, we propose it is due to sensory hypersensitivity. In patients, MTZ slowed disease progression or induced significant improvements for 10/16 MBAS-items of the M1 social behavior area: 4/7 items of the M2 oro-facial/respiratory area and 8/14 items of the M3 motor/physical signs area.RESULTSIn HET mice, MTZ preserved motor learning from deterioration and normalized parvalbumin levels in the primary motor cortex. Moreover, MTZ rescued the aberrant open-arm preference behavior observed in HET mice in the elevated plus-maze (EPM) and normalized parvalbumin expression in the barrel cortex. Since whisker clipping also abolished the EPM-related phenotype, we propose it is due to sensory hypersensitivity. In patients, MTZ slowed disease progression or induced significant improvements for 10/16 MBAS-items of the M1 social behavior area: 4/7 items of the M2 oro-facial/respiratory area and 8/14 items of the M3 motor/physical signs area.This study provides the first evidence that long-term treatment of adult female heterozygous Mecp2tm1.1Bird mice and adult Rett patients with the antidepressant mirtazapine is well tolerated and that it protects from disease progression and improves motor, sensory, and behavioral symptoms.CONCLUSIONSThis study provides the first evidence that long-term treatment of adult female heterozygous Mecp2tm1.1Bird mice and adult Rett patients with the antidepressant mirtazapine is well tolerated and that it protects from disease progression and improves motor, sensory, and behavioral symptoms.
Background Rett syndrome (RTT), an X-linked neurodevelopmental rare disease mainly caused by MECP2-gene mutations, is a prototypic intellectual disability disorder. Reversibility of RTT-like phenotypes in an adult mouse model lacking the Mecp2-gene has given hope of treating the disease at any age. However, adult RTT patients still urge for new treatments. Given the relationship between RTT and monoamine deficiency, we investigated mirtazapine (MTZ), a noradrenergic and specific-serotonergic antidepressant, as a potential treatment. Methods Adult heterozygous-Mecp2 (HET) female mice (6-months old) were treated for 30 days with 10 mg/kg MTZ and assessed for general health, motor skills, motor learning, and anxiety. Motor cortex, somatosensory cortex, and amygdala were analyzed for parvalbumin expression. Eighty RTT adult female patients harboring a pathogenic MECP2 mutation were randomly assigned to treatment to MTZ for insomnia and mood disorders (mean age = 23.1 [+ or -] 7.5 years, range = 16-47 years; mean MTZ-treatment duration = 1.64 [+ or -] 1.0 years, range = 0.08-5.0 years). Rett clinical severity scale (RCSS) and motor behavior assessment scale (MBAS) were retrospectively analyzed. Results In HET mice, MTZ preserved motor learning from deterioration and normalized parvalbumin levels in the primary motor cortex. Moreover, MTZ rescued the aberrant open-arm preference behavior observed in HET mice in the elevated plus-maze (EPM) and normalized parvalbumin expression in the barrel cortex. Since whisker clipping also abolished the EPM-related phenotype, we propose it is due to sensory hypersensitivity. In patients, MTZ slowed disease progression or induced significant improvements for 10/16 MBAS-items of the M1 social behavior area: 4/7 items of the M2 oro-facial/respiratory area and 8/14 items of the M3 motor/physical signs area. Conclusions This study provides the first evidence that long-term treatment of adult female heterozygous Mecp2.sup.tm1.1Bird mice and adult Rett patients with the antidepressant mirtazapine is well tolerated and that it protects from disease progression and improves motor, sensory, and behavioral symptoms. Keywords: Rett syndrome, Intellectual disability disorders, Irritability/aggressiveness, Motor learning deficits, Antidepressants, Somatosensory cortex, Parvalbumin neurons
Abstract Background Rett syndrome (RTT), an X-linked neurodevelopmental rare disease mainly caused by MECP2-gene mutations, is a prototypic intellectual disability disorder. Reversibility of RTT-like phenotypes in an adult mouse model lacking the Mecp2-gene has given hope of treating the disease at any age. However, adult RTT patients still urge for new treatments. Given the relationship between RTT and monoamine deficiency, we investigated mirtazapine (MTZ), a noradrenergic and specific-serotonergic antidepressant, as a potential treatment. Methods Adult heterozygous-Mecp2 (HET) female mice (6-months old) were treated for 30 days with 10 mg/kg MTZ and assessed for general health, motor skills, motor learning, and anxiety. Motor cortex, somatosensory cortex, and amygdala were analyzed for parvalbumin expression. Eighty RTT adult female patients harboring a pathogenic MECP2 mutation were randomly assigned to treatment to MTZ for insomnia and mood disorders (mean age = 23.1 ± 7.5 years, range = 16–47 years; mean MTZ-treatment duration = 1.64 ± 1.0 years, range = 0.08–5.0 years). Rett clinical severity scale (RCSS) and motor behavior assessment scale (MBAS) were retrospectively analyzed. Results In HET mice, MTZ preserved motor learning from deterioration and normalized parvalbumin levels in the primary motor cortex. Moreover, MTZ rescued the aberrant open-arm preference behavior observed in HET mice in the elevated plus-maze (EPM) and normalized parvalbumin expression in the barrel cortex. Since whisker clipping also abolished the EPM-related phenotype, we propose it is due to sensory hypersensitivity. In patients, MTZ slowed disease progression or induced significant improvements for 10/16 MBAS-items of the M1 social behavior area: 4/7 items of the M2 oro-facial/respiratory area and 8/14 items of the M3 motor/physical signs area. Conclusions This study provides the first evidence that long-term treatment of adult female heterozygous Mecp2 tm1.1Bird mice and adult Rett patients with the antidepressant mirtazapine is well tolerated and that it protects from disease progression and improves motor, sensory, and behavioral symptoms.
Background Rett syndrome (RTT), an X-linked neurodevelopmental rare disease mainly caused by MECP2-gene mutations, is a prototypic intellectual disability disorder. Reversibility of RTT-like phenotypes in an adult mouse model lacking the Mecp2-gene has given hope of treating the disease at any age. However, adult RTT patients still urge for new treatments. Given the relationship between RTT and monoamine deficiency, we investigated mirtazapine (MTZ), a noradrenergic and specific-serotonergic antidepressant, as a potential treatment. Methods Adult heterozygous-Mecp2 (HET) female mice (6-months old) were treated for 30 days with 10 mg/kg MTZ and assessed for general health, motor skills, motor learning, and anxiety. Motor cortex, somatosensory cortex, and amygdala were analyzed for parvalbumin expression. Eighty RTT adult female patients harboring a pathogenic MECP2 mutation were randomly assigned to treatment to MTZ for insomnia and mood disorders (mean age = 23.1 ± 7.5 years, range = 16–47 years; mean MTZ-treatment duration = 1.64 ± 1.0 years, range = 0.08–5.0 years). Rett clinical severity scale (RCSS) and motor behavior assessment scale (MBAS) were retrospectively analyzed. Results In HET mice, MTZ preserved motor learning from deterioration and normalized parvalbumin levels in the primary motor cortex. Moreover, MTZ rescued the aberrant open-arm preference behavior observed in HET mice in the elevated plus-maze (EPM) and normalized parvalbumin expression in the barrel cortex. Since whisker clipping also abolished the EPM-related phenotype, we propose it is due to sensory hypersensitivity. In patients, MTZ slowed disease progression or induced significant improvements for 10/16 MBAS-items of the M1 social behavior area: 4/7 items of the M2 oro-facial/respiratory area and 8/14 items of the M3 motor/physical signs area. Conclusions This study provides the first evidence that long-term treatment of adult female heterozygous Mecp2tm1.1Bird mice and adult Rett patients with the antidepressant mirtazapine is well tolerated and that it protects from disease progression and improves motor, sensory, and behavioral symptoms.
Rett syndrome (RTT), an X-linked neurodevelopmental rare disease mainly caused by MECP2-gene mutations, is a prototypic intellectual disability disorder. Reversibility of RTT-like phenotypes in an adult mouse model lacking the Mecp2-gene has given hope of treating the disease at any age. However, adult RTT patients still urge for new treatments. Given the relationship between RTT and monoamine deficiency, we investigated mirtazapine (MTZ), a noradrenergic and specific-serotonergic antidepressant, as a potential treatment. Adult heterozygous-Mecp2 (HET) female mice (6-months old) were treated for 30 days with 10 mg/kg MTZ and assessed for general health, motor skills, motor learning, and anxiety. Motor cortex, somatosensory cortex, and amygdala were analyzed for parvalbumin expression. Eighty RTT adult female patients harboring a pathogenic MECP2 mutation were randomly assigned to treatment to MTZ for insomnia and mood disorders (mean age = 23.1 [+ or -] 7.5 years, range = 16-47 years; mean MTZ-treatment duration = 1.64 [+ or -] 1.0 years, range = 0.08-5.0 years). Rett clinical severity scale (RCSS) and motor behavior assessment scale (MBAS) were retrospectively analyzed. In HET mice, MTZ preserved motor learning from deterioration and normalized parvalbumin levels in the primary motor cortex. Moreover, MTZ rescued the aberrant open-arm preference behavior observed in HET mice in the elevated plus-maze (EPM) and normalized parvalbumin expression in the barrel cortex. Since whisker clipping also abolished the EPM-related phenotype, we propose it is due to sensory hypersensitivity. In patients, MTZ slowed disease progression or induced significant improvements for 10/16 MBAS-items of the M1 social behavior area: 4/7 items of the M2 oro-facial/respiratory area and 8/14 items of the M3 motor/physical signs area. This study provides the first evidence that long-term treatment of adult female heterozygous Mecp2.sup.tm1.1Bird mice and adult Rett patients with the antidepressant mirtazapine is well tolerated and that it protects from disease progression and improves motor, sensory, and behavioral symptoms.
Rett syndrome (RTT), an X-linked neurodevelopmental rare disease mainly caused by MECP2-gene mutations, is a prototypic intellectual disability disorder. Reversibility of RTT-like phenotypes in an adult mouse model lacking the Mecp2-gene has given hope of treating the disease at any age. However, adult RTT patients still urge for new treatments. Given the relationship between RTT and monoamine deficiency, we investigated mirtazapine (MTZ), a noradrenergic and specific-serotonergic antidepressant, as a potential treatment. Adult heterozygous-Mecp2 (HET) female mice (6-months old) were treated for 30 days with 10 mg/kg MTZ and assessed for general health, motor skills, motor learning, and anxiety. Motor cortex, somatosensory cortex, and amygdala were analyzed for parvalbumin expression. Eighty RTT adult female patients harboring a pathogenic MECP2 mutation were randomly assigned to treatment to MTZ for insomnia and mood disorders (mean age = 23.1 ± 7.5 years, range = 16-47 years; mean MTZ-treatment duration = 1.64 ± 1.0 years, range = 0.08-5.0 years). Rett clinical severity scale (RCSS) and motor behavior assessment scale (MBAS) were retrospectively analyzed. In HET mice, MTZ preserved motor learning from deterioration and normalized parvalbumin levels in the primary motor cortex. Moreover, MTZ rescued the aberrant open-arm preference behavior observed in HET mice in the elevated plus-maze (EPM) and normalized parvalbumin expression in the barrel cortex. Since whisker clipping also abolished the EPM-related phenotype, we propose it is due to sensory hypersensitivity. In patients, MTZ slowed disease progression or induced significant improvements for 10/16 MBAS-items of the M1 social behavior area: 4/7 items of the M2 oro-facial/respiratory area and 8/14 items of the M3 motor/physical signs area. This study provides the first evidence that long-term treatment of adult female heterozygous Mecp2 mice and adult Rett patients with the antidepressant mirtazapine is well tolerated and that it protects from disease progression and improves motor, sensory, and behavioral symptoms.
ArticleNumber 26
Audience Academic
Author Flores Gutiérrez, Javier
Hayek, Joussef
Leoncini, Silvia
Natali, Giulia
Tongiorgi, Enrico
De Felice, Claudio
Signorini, Cinzia
Author_xml – sequence: 1
  givenname: Javier
  surname: Flores Gutiérrez
  fullname: Flores Gutiérrez, Javier
– sequence: 2
  givenname: Claudio
  surname: De Felice
  fullname: De Felice, Claudio
– sequence: 3
  givenname: Giulia
  surname: Natali
  fullname: Natali, Giulia
– sequence: 4
  givenname: Silvia
  surname: Leoncini
  fullname: Leoncini, Silvia
– sequence: 5
  givenname: Cinzia
  surname: Signorini
  fullname: Signorini, Cinzia
– sequence: 6
  givenname: Joussef
  surname: Hayek
  fullname: Hayek, Joussef
– sequence: 7
  givenname: Enrico
  orcidid: 0000-0003-0485-0603
  surname: Tongiorgi
  fullname: Tongiorgi, Enrico
BackLink https://www.ncbi.nlm.nih.gov/pubmed/32988385$$D View this record in MEDLINE/PubMed
BookMark eNp9kt-K1DAUxousuH_0BbyQgCCCdDdNkzS5EZbFPwsriuitIU1PZzK0yZikKztP4LWP6JOY2RmHnUUkFw05v-_L6cl3XBw476Aonlb4tKoEP4tVxYUsMcElljUR5epBcZQLvKwkYwe7PW0Oi-MYFxjzmjD2qDisiRSiFuyo-PYp-AQm2WtAwQ-AfI9GG5Je6aV1gKxDupuGhHoYdS5_ALMkr85-__yVMQNIuw4tdbLgUkQ_bJqjz5ASijeuC36Ex8XDXg8Rnmy_J8XXt2--XLwvrz6-u7w4vyoNw3JVauiJAFNrKViHm76RuelW65YSKRvTGd7zlrOWMiNkS0iviRbYcMwNxYLg-qS43Ph2Xi_UMthRhxvltVW3Bz7MlA7JmgEUSEMw7xmmraFU1gKYoJoL1mpuMCPZ6_XGazm1I3Qm_1rQw57pfsXZuZr5a9VkMaZrg5dbg-C_TxCTGm00MAzagZ-iIpQ2dUUJqTL6_B668FNweVSZYlVDeX3b0Zaa5SdQ1vU-32vWpuqc140QUjKRqdN_UHl1kJ8qR6e3-XxP8OKOYA56SPPohylZ7-I--OzuRHaj-BujDJANYIKPMUC_Qyqs1llVm6yqnFV1m1W1yiJxT2Rs0uvLc992-J_0D1Ww7MY
CitedBy_id crossref_primary_10_1016_j_expneurol_2022_114056
crossref_primary_10_1016_j_nbd_2022_105636
crossref_primary_10_1186_s11689_021_09409_7
crossref_primary_10_3389_fnbeh_2022_974692
crossref_primary_10_3390_ijms251910469
crossref_primary_10_3389_fnins_2022_825063
crossref_primary_10_2147_DDDT_S383133
crossref_primary_10_3390_biom14101230
crossref_primary_10_3390_cells13242077
Cites_doi 10.1016/j.cell.2016.09.039
10.1002/mds.870050303
10.1007/s10354-016-0492-8
10.1002/ana.22124
10.3390/ijms19010097
10.1007/s10882-015-9427-3
10.1038/nmeth.2019
10.1097/00004714-199704001-00005
10.1038/nprot.2006.170
10.1093/hmg/dds406
10.1111/j.1527-3458.2001.tb00198.x
10.1371/journal.pone.0138113
10.1016/j.lfs.2015.10.025
10.1177/08830738050200090501
10.1016/j.physbeh.2015.03.035
10.1242/dmm.011007
10.1016/bs.pbr.2016.04.012
10.1111/gbb.12133
10.1007/s11011-018-0316-1
10.1093/bfgp/elw023
10.4103/0976-0105.177703
10.1016/j.resp.2007.08.009
10.1126/science.1138389
10.3758/BF03193146
10.1038/nrneurol.2016.186
10.1523/ENEURO.0086-18.2018
10.1016/B978-0-12-375674-9.10010-2
10.1177/0269881116681399
10.1038/85899
10.1002/ana.410140412
10.1002/dev.420190203
10.1007/s11325-012-0654-x
10.1016/j.braindev.2018.08.008
10.1016/j.braindev.2008.04.007
10.1203/PDR.0b013e3182242461
10.1016/j.neuron.2007.10.001
10.1097/AJP.0b013e318274b6bd
10.1016/j.conb.2019.07.002
10.1016/j.neuroscience.2010.07.010
10.1016/j.neuron.2015.07.033
10.1002/ana.410340220
10.1038/nature08002
10.1093/hmg/ddi016
10.1111/j.1460-9568.2007.05466.x
10.1038/s41583-018-0006-3
10.2174/1389203717666161213115746
10.1136/jmedgenet-2013-102113
10.1016/j.psyneuen.2007.02.008
10.1186/s13023-018-0786-6
10.1016/j.expneurol.2009.12.007
10.1073/pnas.1618210114
10.1002/mds.21276
10.1517/14656566.6.4.631
10.1186/s11689-015-9127-4
10.1093/hmg/ddx087
10.1073/pnas.1803792115
10.1038/srep19796
10.1073/pnas.0912257106
10.1016/j.braindev.2008.05.003
10.1016/j.braindev.2007.04.001
10.1038/nature11556
10.1016/j.pediatrneurol.2015.06.003
10.1038/13810
10.1002/acn3.468
10.1002/ajmg.a.33314
10.1002/brb3.1285
10.1111/acer.13484
ContentType Journal Article
Copyright COPYRIGHT 2020 BioMed Central Ltd.
2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2020
Copyright_xml – notice: COPYRIGHT 2020 BioMed Central Ltd.
– notice: 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2020
DBID AAYXX
CITATION
NPM
3V.
7RV
7TK
7X7
7XB
88E
8FD
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FR3
FYUFA
GHDGH
K9.
KB0
M0S
M1P
NAPCQ
P64
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
PSYQQ
RC3
7X8
5PM
DOA
DOI 10.1186/s11689-020-09328-z
DatabaseName CrossRef
PubMed
ProQuest Central (Corporate)
Nursing & Allied Health Database
Neurosciences Abstracts
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Technology Research Database
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni Edition)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Engineering Research Database
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Database (Alumni Edition)
Health & Medical Collection (Alumni Edition)
Medical Database
Nursing & Allied Health Premium
Biotechnology and BioEngineering Abstracts
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest One Psychology
Genetics Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest One Psychology
Technology Research Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
ProQuest Health & Medical Research Collection
Genetics Abstracts
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Nursing & Allied Health Source
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Neurosciences Abstracts
ProQuest Hospital Collection (Alumni)
Biotechnology and BioEngineering Abstracts
Nursing & Allied Health Premium
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest Nursing & Allied Health Source (Alumni)
Engineering Research Database
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic



Publicly Available Content Database

PubMed
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1866-1955
EndPage 20
ExternalDocumentID oai_doaj_org_article_e9c206f504bc44938e584a685ba6c052
PMC7523042
A637889958
32988385
10_1186_s11689_020_09328_z
Genre Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations United States--US
GeographicLocations_xml – name: United States--US
GrantInformation_xml – fundername: ;
GroupedDBID 0R~
29L
2JY
4.4
53G
5GY
5VS
67Z
6NX
7RV
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABIVO
ABUWG
ACGFS
ACPRK
ADBBV
ADRAZ
ADUKV
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AOIJS
BA0
BAPOH
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CAG
CCPQU
CITATION
CSCUP
DU5
EBLON
EBS
EMOBN
F5P
FEDTE
FYUFA
GROUPED_DOAJ
GXS
HMCUK
HVGLF
HYE
IAO
IHR
IHW
INH
INR
IPY
ITC
IXC
I~X
KOV
KQ8
M1P
M48
NAPCQ
O9I
OK1
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
PSYQQ
QOS
RBZ
RNS
ROL
RPM
RSV
S27
SDH
SMD
SOJ
T13
U2A
UKHRP
VC2
WK8
NPM
PMFND
3V.
7TK
7XB
8FD
8FK
AZQEC
DWQXO
FR3
K9.
P64
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
PRINS
RC3
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c509z-aef28ec3a985d07f79947baab42997cdc6f6b65b45c89b22fa2a80c606c408203
IEDL.DBID DOA
ISSN 1866-1947
1866-1955
IngestDate Wed Aug 27 01:11:55 EDT 2025
Thu Aug 21 14:08:40 EDT 2025
Fri Jul 11 08:38:54 EDT 2025
Fri Jul 25 09:22:13 EDT 2025
Tue Jun 17 21:36:32 EDT 2025
Tue Jun 10 20:34:59 EDT 2025
Thu May 22 21:18:37 EDT 2025
Thu Apr 03 06:55:22 EDT 2025
Tue Jul 01 02:30:41 EDT 2025
Thu Apr 24 23:02:25 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Intellectual disability disorders
Somatosensory cortex
Irritability/aggressiveness
Parvalbumin neurons
Motor learning deficits
Antidepressants
Rett syndrome
Language English
License Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c509z-aef28ec3a985d07f79947baab42997cdc6f6b65b45c89b22fa2a80c606c408203
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ORCID 0000-0003-0485-0603
OpenAccessLink https://doaj.org/article/e9c206f504bc44938e584a685ba6c052
PMID 32988385
PQID 2451746352
PQPubID 2040182
PageCount 20
ParticipantIDs doaj_primary_oai_doaj_org_article_e9c206f504bc44938e584a685ba6c052
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7523042
proquest_miscellaneous_2447314221
proquest_journals_2451746352
gale_infotracmisc_A637889958
gale_infotracacademiconefile_A637889958
gale_healthsolutions_A637889958
pubmed_primary_32988385
crossref_primary_10_1186_s11689_020_09328_z
crossref_citationtrail_10_1186_s11689_020_09328_z
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2020-09-28
PublicationDateYYYYMMDD 2020-09-28
PublicationDate_xml – month: 09
  year: 2020
  text: 2020-09-28
  day: 28
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Journal of neurodevelopmental disorders
PublicationTitleAlternate J Neurodev Disord
PublicationYear 2020
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References HY Zoghbi (9328_CR18) 2016; 167
F Della Ragione (9328_CR7) 2016; 12
J Guy (9328_CR16) 2007; 315
AL Reiss (9328_CR17) 1993; 34
A Rett (9328_CR2) 2016; 166
VA Cuddapah (9328_CR8) 2014; 51
E Roze (9328_CR13) 2007; 22
AH Veenema (9328_CR56) 2007; 32
9328_CR24
BL Pearson (9328_CR58) 2015; 146
9328_CR25
9328_CR69
JPK Ip (9328_CR14) 2018; 19
J Downs (9328_CR62) 2010; 152A
B Hagberg (9328_CR1) 1983; 14
A Kimbrough (9328_CR66) 2017; 41
DR Connolly (9328_CR6) 2019; 59
J Schindelin (9328_CR39) 2012; 9
S Fehr (9328_CR4) 2011; 70
EA Permyakov (9328_CR47) 2017; 18
CC Barney (9328_CR64) 2015; 27
J Mancini (9328_CR26) 2018; 5
N Kishi (9328_CR50) 2010; 222
DM Katz (9328_CR20) 2012; 5
J Guy (9328_CR30) 2001; 27
M Santos (9328_CR22) 2010; 170
JA Cardin (9328_CR65) 2009; 459
9328_CR19
X Jiang (9328_CR46) 2016; 226
SAK Anttila (9328_CR33) 2006; 7
M-L Riittinen (9328_CR67) 1986; 19
SB Nelson (9328_CR48) 2015; 87
GD Burrows (9328_CR28) 1997; 17
A Nair (9328_CR34) 2016; 7
J Karsten (9328_CR51) 2017; 31
PM FitzGerald (9328_CR52) 1990; 5
9328_CR55
9328_CR53
RE Amir (9328_CR5) 1999; 23
A Erlandson (9328_CR10) 2005; 20
FJ Symons (9328_CR61) 2019; 9
RC Samaco (9328_CR42) 2013; 22
FJ Symons (9328_CR63) 2013; 29
D Young (9328_CR70) 2007; 29
A Bhattacherjee (9328_CR60) 2017; 114
M Chahrour (9328_CR12) 2007; 56
SC Landis (9328_CR32) 2012; 490
RM Deacon (9328_CR36) 2006; 1
M Carotenuto (9328_CR68) 2013; 17
RMJ Deacon (9328_CR35) 2013; 75
9328_CR49
RC Samaco (9328_CR21) 2009; 106
A Renieri (9328_CR40) 2009; 31
KV Barnes (9328_CR44) 2015; 7
TJ Flanigan (9328_CR45) 2014; 13
P Moretti (9328_CR57) 2005; 14
S Corchón (9328_CR72) 2018; 33
P Przanowski (9328_CR9) 2018; 115
F Faul (9328_CR41) 2007; 39
RH Mount (9328_CR43) 2001; 23
DC Tarquinio (9328_CR15) 2015; 53
KWE Neul (9328_CR11) 2010; 68
A Vogel Ciernia (9328_CR37) 2017; 26
CB Buchanan (9328_CR71) 2019; 41
P Hartmann (9328_CR29) 1999; 59
9328_CR38
A Bhattacherjee (9328_CR59) 2017; 19
S Dutta (9328_CR54) 2016; 152
T Bittolo (9328_CR31) 2016; 6
T Temudo (9328_CR23) 2009; 31
H Leonard (9328_CR3) 2017; 13
A Szegedi (9328_CR27) 2005; 6
References_xml – volume: 167
  start-page: 293
  issue: 2
  year: 2016
  ident: 9328_CR18
  publication-title: Cell.
  doi: 10.1016/j.cell.2016.09.039
– volume: 5
  start-page: 195
  issue: 3
  year: 1990
  ident: 9328_CR52
  publication-title: Mov Disord
  doi: 10.1002/mds.870050303
– volume: 166
  start-page: 322
  issue: 11–12
  year: 2016
  ident: 9328_CR2
  publication-title: Wien Med Wochenschr
  doi: 10.1007/s10354-016-0492-8
– volume: 68
  start-page: 944
  issue: 6
  year: 2010
  ident: 9328_CR11
  publication-title: Ann Neurol
  doi: 10.1002/ana.22124
– volume: 19
  start-page: 97
  issue: 1
  year: 2017
  ident: 9328_CR59
  publication-title: Int J Mol Sci
  doi: 10.3390/ijms19010097
– volume: 27
  start-page: 417
  issue: 4
  year: 2015
  ident: 9328_CR64
  publication-title: J Dev Phys Disabil
  doi: 10.1007/s10882-015-9427-3
– volume: 9
  start-page: 676
  issue: 7
  year: 2012
  ident: 9328_CR39
  publication-title: Nat Methods
  doi: 10.1038/nmeth.2019
– volume: 17
  start-page: 34S
  year: 1997
  ident: 9328_CR28
  publication-title: J Clin Psychopharmacol
  doi: 10.1097/00004714-199704001-00005
– volume: 1
  start-page: 1117
  issue: 3
  year: 2006
  ident: 9328_CR36
  publication-title: Nat Protoc
  doi: 10.1038/nprot.2006.170
– volume: 22
  start-page: 96
  issue: 1
  year: 2013
  ident: 9328_CR42
  publication-title: Hum Mol Genet
  doi: 10.1093/hmg/dds406
– volume: 7
  start-page: 249
  issue: 3
  year: 2006
  ident: 9328_CR33
  publication-title: CNS Drug Rev
  doi: 10.1111/j.1527-3458.2001.tb00198.x
– ident: 9328_CR69
  doi: 10.1371/journal.pone.0138113
– ident: 9328_CR38
– volume: 152
  start-page: 244
  year: 2016
  ident: 9328_CR54
  publication-title: Life Sci
  doi: 10.1016/j.lfs.2015.10.025
– volume: 59
  start-page: 159
  issue: 1
  year: 1999
  ident: 9328_CR29
  publication-title: Am Fam Physician
– volume: 20
  start-page: 727
  issue: 9
  year: 2005
  ident: 9328_CR10
  publication-title: J Child Neurol
  doi: 10.1177/08830738050200090501
– volume: 146
  start-page: 98
  year: 2015
  ident: 9328_CR58
  publication-title: Physiol Behav
  doi: 10.1016/j.physbeh.2015.03.035
– volume: 5
  start-page: 733
  issue: 6
  year: 2012
  ident: 9328_CR20
  publication-title: Dis Model Mech
  doi: 10.1242/dmm.011007
– volume: 226
  start-page: 81
  year: 2016
  ident: 9328_CR46
  publication-title: Prog Brain Res
  doi: 10.1016/bs.pbr.2016.04.012
– volume: 13
  start-page: 488
  issue: 5
  year: 2014
  ident: 9328_CR45
  publication-title: Genes Brain Behav
  doi: 10.1111/gbb.12133
– volume: 33
  start-page: 1801
  issue: 6
  year: 2018
  ident: 9328_CR72
  publication-title: Metab Brain Dis
  doi: 10.1007/s11011-018-0316-1
– volume: 12
  start-page: elw023
  year: 2016
  ident: 9328_CR7
  publication-title: Brief Funct Genomics
  doi: 10.1093/bfgp/elw023
– volume: 7
  start-page: 27
  issue: 2
  year: 2016
  ident: 9328_CR34
  publication-title: J Basic Clin Pharm
  doi: 10.4103/0976-0105.177703
– ident: 9328_CR25
  doi: 10.1016/j.resp.2007.08.009
– volume: 315
  start-page: 1143
  issue: 5815
  year: 2007
  ident: 9328_CR16
  publication-title: Science.
  doi: 10.1126/science.1138389
– volume: 39
  start-page: 175
  issue: 2
  year: 2007
  ident: 9328_CR41
  publication-title: Behav Res Methods
  doi: 10.3758/BF03193146
– volume: 13
  start-page: 37
  issue: 1
  year: 2017
  ident: 9328_CR3
  publication-title: Nat Rev Neurol
  doi: 10.1038/nrneurol.2016.186
– ident: 9328_CR49
  doi: 10.1523/ENEURO.0086-18.2018
– ident: 9328_CR53
  doi: 10.1016/B978-0-12-375674-9.10010-2
– volume: 31
  start-page: 327
  issue: 3
  year: 2017
  ident: 9328_CR51
  publication-title: J Psychopharmacol (Oxf)
  doi: 10.1177/0269881116681399
– volume: 27
  start-page: 322
  issue: 3
  year: 2001
  ident: 9328_CR30
  publication-title: Nat Genet
  doi: 10.1038/85899
– volume: 14
  start-page: 471
  issue: 4
  year: 1983
  ident: 9328_CR1
  publication-title: Ann Neurol
  doi: 10.1002/ana.410140412
– volume: 19
  start-page: 105
  issue: 2
  year: 1986
  ident: 9328_CR67
  publication-title: Dev Psychobiol
  doi: 10.1002/dev.420190203
– volume: 17
  start-page: 93
  issue: 1
  year: 2013
  ident: 9328_CR68
  publication-title: Sleep Breath
  doi: 10.1007/s11325-012-0654-x
– volume: 41
  start-page: 123
  issue: 2
  year: 2019
  ident: 9328_CR71
  publication-title: Brain and Development
  doi: 10.1016/j.braindev.2018.08.008
– volume: 31
  start-page: 208
  issue: 3
  year: 2009
  ident: 9328_CR40
  publication-title: Brain and Development
  doi: 10.1016/j.braindev.2008.04.007
– volume: 70
  start-page: 313
  issue: 3
  year: 2011
  ident: 9328_CR4
  publication-title: Pediatr Res
  doi: 10.1203/PDR.0b013e3182242461
– volume: 56
  start-page: 422
  issue: 3
  year: 2007
  ident: 9328_CR12
  publication-title: Neuron.
  doi: 10.1016/j.neuron.2007.10.001
– volume: 29
  start-page: 744
  issue: 8
  year: 2013
  ident: 9328_CR63
  publication-title: Clin J Pain
  doi: 10.1097/AJP.0b013e318274b6bd
– volume: 59
  start-page: 174
  year: 2019
  ident: 9328_CR6
  publication-title: Curr Opin Neurobiol
  doi: 10.1016/j.conb.2019.07.002
– volume: 170
  start-page: 453
  issue: 2
  year: 2010
  ident: 9328_CR22
  publication-title: Neuroscience.
  doi: 10.1016/j.neuroscience.2010.07.010
– volume: 87
  start-page: 684
  issue: 4
  year: 2015
  ident: 9328_CR48
  publication-title: Neuron.
  doi: 10.1016/j.neuron.2015.07.033
– volume: 34
  start-page: 227
  issue: 2
  year: 1993
  ident: 9328_CR17
  publication-title: Ann Neurol
  doi: 10.1002/ana.410340220
– volume: 459
  start-page: 663
  issue: 7247
  year: 2009
  ident: 9328_CR65
  publication-title: Nature.
  doi: 10.1038/nature08002
– volume: 14
  start-page: 205
  issue: 2
  year: 2005
  ident: 9328_CR57
  publication-title: Hum Mol Genet
  doi: 10.1093/hmg/ddi016
– ident: 9328_CR24
  doi: 10.1111/j.1460-9568.2007.05466.x
– volume: 19
  start-page: 368
  issue: 6
  year: 2018
  ident: 9328_CR14
  publication-title: Nat Rev Neurosci
  doi: 10.1038/s41583-018-0006-3
– volume: 18
  start-page: 780
  issue: 8
  year: 2017
  ident: 9328_CR47
  publication-title: Curr Protein Pept Sci
  doi: 10.2174/1389203717666161213115746
– volume: 51
  start-page: 152
  issue: 3
  year: 2014
  ident: 9328_CR8
  publication-title: J Med Genet
  doi: 10.1136/jmedgenet-2013-102113
– ident: 9328_CR55
– volume: 32
  start-page: 437
  issue: 5
  year: 2007
  ident: 9328_CR56
  publication-title: Psychoneuroendocrinology.
  doi: 10.1016/j.psyneuen.2007.02.008
– ident: 9328_CR19
  doi: 10.1186/s13023-018-0786-6
– volume: 222
  start-page: 51
  issue: 1
  year: 2010
  ident: 9328_CR50
  publication-title: Exp Neurol
  doi: 10.1016/j.expneurol.2009.12.007
– volume: 114
  start-page: E6952
  issue: 33
  year: 2017
  ident: 9328_CR60
  publication-title: Proc Natl Acad Sci
  doi: 10.1073/pnas.1618210114
– volume: 22
  start-page: 387
  issue: 3
  year: 2007
  ident: 9328_CR13
  publication-title: Mov Disord Off J Mov Disord Soc
  doi: 10.1002/mds.21276
– volume: 6
  start-page: 631
  issue: 4
  year: 2005
  ident: 9328_CR27
  publication-title: Expert Opin Pharmacother
  doi: 10.1517/14656566.6.4.631
– volume: 7
  start-page: 30
  issue: 1
  year: 2015
  ident: 9328_CR44
  publication-title: J Neurodev Disord
  doi: 10.1186/s11689-015-9127-4
– volume: 26
  start-page: 1839
  issue: 10
  year: 2017
  ident: 9328_CR37
  publication-title: Hum Mol Genet
  doi: 10.1093/hmg/ddx087
– volume: 115
  start-page: 7991
  issue: 31
  year: 2018
  ident: 9328_CR9
  publication-title: Proc Natl Acad Sci
  doi: 10.1073/pnas.1803792115
– volume: 75
  start-page: 2609
  year: 2013
  ident: 9328_CR35
  publication-title: J Vis Exp
– volume: 6
  start-page: 19796
  issue: 1
  year: 2016
  ident: 9328_CR31
  publication-title: Sci Rep
  doi: 10.1038/srep19796
– volume: 23
  start-page: 129
  issue: 3–4
  year: 2001
  ident: 9328_CR43
  publication-title: Disabil Rehabil
– volume: 106
  start-page: 21966
  issue: 51
  year: 2009
  ident: 9328_CR21
  publication-title: Proc Natl Acad Sci
  doi: 10.1073/pnas.0912257106
– volume: 31
  start-page: 46
  issue: 1
  year: 2009
  ident: 9328_CR23
  publication-title: Brain and Development
  doi: 10.1016/j.braindev.2008.05.003
– volume: 29
  start-page: 609
  issue: 10
  year: 2007
  ident: 9328_CR70
  publication-title: Brain and Development
  doi: 10.1016/j.braindev.2007.04.001
– volume: 490
  start-page: 187
  issue: 7419
  year: 2012
  ident: 9328_CR32
  publication-title: Nature.
  doi: 10.1038/nature11556
– volume: 53
  start-page: 402
  issue: 5
  year: 2015
  ident: 9328_CR15
  publication-title: Pediatr Neurol
  doi: 10.1016/j.pediatrneurol.2015.06.003
– volume: 23
  start-page: 185
  issue: 2
  year: 1999
  ident: 9328_CR5
  publication-title: Nat Genet
  doi: 10.1038/13810
– volume: 5
  start-page: 118
  issue: 2
  year: 2018
  ident: 9328_CR26
  publication-title: Ann Clin Transl Neurol
  doi: 10.1002/acn3.468
– volume: 152A
  start-page: 1197
  issue: 5
  year: 2010
  ident: 9328_CR62
  publication-title: Am J Med Genet A
  doi: 10.1002/ajmg.a.33314
– volume: 9
  start-page: e01285
  issue: 5
  year: 2019
  ident: 9328_CR61
  publication-title: Brain Behav
  doi: 10.1002/brb3.1285
– volume: 41
  start-page: 1886
  issue: 11
  year: 2017
  ident: 9328_CR66
  publication-title: Alcohol Clin Exp Res
  doi: 10.1111/acer.13484
SSID ssj0063255
Score 2.2613966
Snippet Rett syndrome (RTT), an X-linked neurodevelopmental rare disease mainly caused by MECP2-gene mutations, is a prototypic intellectual disability disorder....
Background Rett syndrome (RTT), an X-linked neurodevelopmental rare disease mainly caused by MECP2-gene mutations, is a prototypic intellectual disability...
Abstract Background Rett syndrome (RTT), an X-linked neurodevelopmental rare disease mainly caused by MECP2-gene mutations, is a prototypic intellectual...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 26
SubjectTerms Age
Amygdala
Analysis
Animals
Antidepressants
Behavior
Biopsy
Cortex (barrel)
Cortex (motor)
Deoxyribonucleic acid
DNA
Ethanol
Females
Gene mutation
Genetic aspects
Genotype & phenotype
Hypersensitivity
Intellectual disabilities
Intellectual disability disorders
Irritability/aggressiveness
Laboratories
MeCP2 protein
Methyl-CpG binding protein
Mirtazapine
Mood
Motor learning deficits
Motor skill
Motor skill learning
Mutation
Neurodevelopmental disorders
Norepinephrine
Parvalbumin
Patients
Phenotypes
Rare diseases
Rett syndrome
Rodents
Sleep disorders
Social aspects
Social behavior
Somatosensory cortex
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Pi9QwFA-6gngR_1tdNYLgYSnTSdI0OckqLouwIuLCnAxJmuiA2xl3Zi_zCTz7Ef0kvpemdYuw1-YF0rz_ycvvEfJKVLzBVwdg_bQvRWN9aXWrS67BWbmao13GaouP8vhUfFjUi3zgtslllYNNTIa6XXk8I58xgZjK4B7Zm_XPErtG4e1qbqFxndxA6DIs6WoWY8IlOUtdTxHTrYRkvRkezSg528znEouFIHmCnJ6pcjdxTAm__38rfclNTUsoL_mkozvkdg4m6WHP_bvkWujukZsn-br8Pvn6qUdhAItGsYyQriI9W0K8vbNrIKDLjib8DRrDGSyBngS_ZgezP79-U-xST23X0gy8uqF4Yks_h-2WDigHD8jp0fsv747L3FCh9BAX7EobIlPBc6tV3VZNbDRsirPWoVNqfOtllE7WTtReacdYtMyqykOO47EvdcUfkr1u1YXHhLYu6sCVsJhvAcNtkFW03lkIGWMUbUHmw24an9HGsenFD5OyDiVNzwEDHDCJA2ZXkINxzrrH2riS-i0yaaREnOz0YXX-zWS1M0F7VslYV8J5ITRXAQIuK1XtrPRVzQryAlls-keno7abQ4k4-xpEqiCvEwXqO_yAt_nZAmwDImdNKPcnlKCnfjo8iJHJdmJj_kl1QV6OwzgTa9-6sLpAGtFwPKqbF-RRL3XjT3OmleKqLkgzkcfJrkxHuuX3hCLepPsA9uTqZT0lt1ivJCVT-2Rve34RnkEYtnXPk679BSouLus
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LixQxEA7rCuJFfNu6agTBw9JuT5JOJweRVVwWYUTEgb2FJJ3owG7PODMLOr_Asz_RX2JV-sE2Lp68dqqbTj1SVUnlK0Kei4JXeOsAVj_tc1FZn1td65xrcFau5LguY7XFB3k8E-9PypMd0rc76hi4vjS1w35Ss9Xpy-_ffrwGg3-VDF7Jg_VkIrHwBxIhyM-ZyrdXyFXwTBUa6lQMpwqSs9QFFTHeckjeq_4SzaXfGDmqhOf_96p9wW2NSyov-Kijm-RGF1zSw1YbbpGd0Nwm16bd8fkdYj62qAywwlEsK6SLSM_mMPWtXQIBnTc04XHQGM7gF-g0-CWj-we_f_6i2Lae2qamHRLrmuIWLv0UNhvawx7cJbOjd5_fHuddh4XcQ6CwzW2ITAXPrVZlXVSx0sAVZ61DL1X52ssonSydKL3SjrFomVWFh6THY6Pqgt8ju82iCQ8IrV3UgSthMQEDDbBBFtF6ZyGGjFHUGZn07DS-gx_HLhinJqUhSppWBAZEYJIIzDYj-8M7yxZ845_Ub1BKAyUCZ6cHi9UX09mhCdqzQsayEM4LobkKEIFZqUpnpS9KlpGnKGPT3kIdzN8cSgTe17pUGXmRKFAlYQLedvcYgA0IpTWi3BtRguH68XCvR6bXe8MEQodDFAh_8mwYxjexGK4Ji3OkERXHvbtJRu63ajdMmjOtFFdlRqqRQo64Mh5p5l8TrHiVDgjYw__BxkfkOmttKWdqj-xuVufhMURvG_ckmeQf83U_OQ
  priority: 102
  providerName: Scholars Portal
Title Protective role of mirtazapine in adult female Mecp2+/− mice and patients with Rett syndrome
URI https://www.ncbi.nlm.nih.gov/pubmed/32988385
https://www.proquest.com/docview/2451746352
https://www.proquest.com/docview/2447314221
https://pubmed.ncbi.nlm.nih.gov/PMC7523042
https://doaj.org/article/e9c206f504bc44938e584a685ba6c052
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBZtCqWX0nfdplsVCj0Es15J1uOYlIRQ2BBCA3sTkizRhcS7dDeX_QU99yf2l3RG9i5rCu2lFx-sMcjzHnv0DSEfRcUVnjoA72dCKZQLpTONKbmBYOVrjn4Zuy0u5Pm1-DKrZ3ujvrAnrIMH7hg3jiawSqa6Ej4IYbiOEDKd1LV3MlR19r4Q87bFVOeDJWd53imiuZVQpqvtcRktx6vJRGKbEJRNUM0zXW4GISkj9__pn_cC1LB5ci8anT0hj_s0kh53239K7sX2GXk47X-UPyf2ssNfAF9GsYGQLhK9nUOmvXFLIKDzlmbkDZriLWyBTmNYMno0_vXjJ8UB9dS1De0xV1cUP9bSq7he0y3AwQtyfXb69fN52c9SKAOkBJvSxcR0DNwZXTeVSsoAV7xzHuORCk2QSXpZe1EHbTxjyTGnqwDlTcCR1BV_SQ7aRRtfE9r4ZCIHIWCpBbJ2UVbJBe8gW0xJNAWZbNlpQw80jvMubmwuOLS0nQgsiMBmEdhNQY52zyw7mI2_Up-glHaUCJGdb4Di2F5x7L8UpyDvUca2O2-6M3R7LBFi35haF-RTpkBThxcIrj-xAGxA0KwB5eGAEkw0DJe3emR7F7GyTCBIOOR7sJMPu2V8Etve2ri4QxqhOH6lmxTkVad2u5fmzGjNdV0QNVDIAVeGK-38WwYQV_lXAHvzP9j4ljxinS2VTB-Sg_X3u_gO8rS1H5H7aqZG5MHJ6cXl1SgbKFynQv8GfXg6Sg
linkProvider Directory of Open Access Journals
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwELbKVgIuiH8ChRoJxKGKNrEdxz4g1EKrLe2uqqqVesJ1HAdWotmluxVin4AzD8JD8STM5GdphNRbr_E4Sjzjb8b2-BtCXomIp3jrANBPu1Ck1oVW5zrkGpxVlnDEZcy2GMnBsfh4kpyskN_tXRhMq2wxsQLqfOJwj7zPBHIqg3tk76bfQqwahaerbQmN2iz2_I_vsGSbvd39APp9zdjO9tH7QdhUFQgdOMdFaH3BlHfcapXkUVqkWos0szZDZE5d7mQhM5lkInFKZ4wVllkVOQj0HRZnjji89wZZFRyWMj2yurU9OjhssV9yVtVZRRa5MIb3ttd0lOzP4lhiehIs1yIImlS46LjCqmLA_37hkmPsJm1e8oI7d8mdJnylm7W93SMrvrxPbg6bA_oH5NNBzfsAGEoxcZFOCno2hgh_YacgQMclrRg_aOHP4BPo0Lsp2-j_-fkLxJyntsxpQ_U6o7hHTA_9fE5bXoWH5PhaBvsR6ZWT0j8hNM8K7bkSFld4YGLWy6iwLrMQpBaFyAMSt6NpXMNvjmU2vppqnaOkqTVgQAOm0oBZBGRj2Wdas3tcKb2FSlpKIjN39WBy_tk0E9147VgkiyQSmRNCc-UhxLNSJZmVLkpYQNZRxaa-5rrEF7Mpkdlf60QF5E0lgQgDP-Bsc1EChgG5ujqSax1JQAbXbW7NyDTINDP_5lFAXi6bsSdm25V-coEyIuW4ORgH5HFtdcuf5kwrxVUSkLRjj51R6baU4y8Vb3lanUCwp1d_1jq5NTga7pv93dHeM3Kb1RMmZGqN9ObnF_45BIHz7EUz8yg5ve7J_heoXW16
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Protective+role+of+mirtazapine+in+adult+female+Mecp2+%2B%2F%E2%88%92+mice+and+patients+with+Rett+syndrome&rft.jtitle=Journal+of+neurodevelopmental+disorders&rft.au=Javier+Flores+Guti%C3%A9rrez&rft.au=Claudio+De+Felice&rft.au=Giulia+Natali&rft.au=Silvia+Leoncini&rft.date=2020-09-28&rft.pub=BMC&rft.issn=1866-1947&rft.eissn=1866-1955&rft.volume=12&rft.issue=1&rft.spage=1&rft.epage=20&rft_id=info:doi/10.1186%2Fs11689-020-09328-z&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_e9c206f504bc44938e584a685ba6c052
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1866-1947&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1866-1947&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1866-1947&client=summon